1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin,2005,55(2) :74-108.
2Coleman MP, Gatta G, Verdeechia A, et al. EUROCARE-3 sum- mary:cancer survival in Europe at the end of the 20th century [J]. Ann Oncol,2003,14 (Suppl 5) :v128-49.
3Schiller J H, H arrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung canc- er[J]. N Engl J Med,2002,346(2) :92-8.
4Fossella F,Pereira JR,von Pawel J,et al. Randomized,multina- tional,phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the TAX 326 study group[J]. J Clin Oncol,2003, 21(16) :3016-24.
5Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin a- lone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Meal,2006,355(24) :2542-50.
6Herbst RS,Sun Y,Eberhardt WE, et al. Vandetanib plus do- cetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC) :a double- blind, randomised, phase 3 trial[J]. Lancet Oncol, 2010, 11 (7) :619-26.
8Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer[J]. Eur J Cancer, 2005,41 (16): 2438-48.
9Shi Q, Le X, Abbruzzese JL, et al. Constitutive Spl activity is es sential for differential constitutive expression of vascular endo thelial growth factor in human pancreatic adenocarcinoma[J] Cancer Res, 2001,61 (10) :4143-54.
10Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1,3, and 4 in panereatic cancer cells[J]. Cancer Res,2007,67(7) :3286-94.
3Jansen M, Buchin P, Dreuw B, et al. Prognostic factors for development of peritoneal careinosis in stomach carcinoma. Chirurg, 2001,72: 561-564.
4Li C, Kim S, Lai JF, et al. Advanced gastric carcinoma with signet ring cell histology. Oncology, 2007, 72: 64-68.
5Lee KH, Choi EY, Hyun MS, et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF induced in vitro invasion in human stomach cancer ceils. Eur Surg Res, 2007, 39 : 208-215.
6Han SU, Lee HY, Lee JH, et al. Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg, 2005, 242: 676-683.
7Cabuk D, Basaran G, Celikel C, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology, 2007, 72: 111-117.
8Yu B, Datta PK, Bagchi S. Stability of the Sp3-DNA complex is promoter-speeifie:Sp3 efficiently competes with Spl for binding to promoters containing multiple Sp-sites. Nucleic Acids Res, 2003, 31 : 5368-5376.
9Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer, 2007, 6:69.
3Spigel DR,Hainsworth JD,Yardley DA,et al. Tracheoesoph-ageal fistula formation in patients with lung cancer treatedwith chemoradiation and bevacizumab[ J]. J Clin Oncol,2010,28(1) :43-48.
4Eisenhauer EA,Therasse P, Boqaerts J, et al. New responseevaluation criteria in solid tumours : revised RECIST guide-line ( version 1. 1)[ J]. Eur J Cancer, 2009,45 (2) : 228-247.
5Dansin E,Cousin S,Lauridant G,et al. Bevacizumab in tho-racic oncology: Results and practical aspects[ J]. Rev Pneu-mol Clin,2013,69(3) : 159-169.
6Miyazaki M,Naoki K,Sato T,et al. A case of advanced lungadenocarcinoma with cavity formation shrunken by bevaci-zumab added on the 3rd course of 6th-line chemotherapy[J]. Gan To Kagaku Ryoho,2012,39(3) :421424.
